Ocular Therapeutix

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company's products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Bedford, US
Size (employees)
118 (est)+32%
Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, US

Key People at Ocular Therapeutix

Antony Mattessich

Antony Mattessich

Chief Executive Officer
Fred Khosravi

Fred Khosravi

Co - Founder, Director & Chairman

Ocular Therapeutix Office Locations

Ocular Therapeutix has an office in Bedford
Bedford, US (HQ)
36 Crosby Drive,

Ocular Therapeutix Data and Metrics

Ocular Therapeutix Financial Metrics

Ocular Therapeutix's revenue was reported to be $1.8 m in FY, 2015

Net income (FY, 2016)

(44.7 m)

Market capitalization (20-Jul-2017)

199.7 m

Closing share price (20-Jul-2017)


Cash (31-Dec-2016)

32.9 m
Ocular Therapeutix's current market capitalization is $199.7 m.
USDFY, 2014FY, 2015FY, 2016


772 k1.8 m

Revenue growth, %


Net Income

(28.6 m)(39.7 m)(44.7 m)
USDFY, 2014FY, 2015FY, 2016


37.4 m30.8 m32.9 m

Accounts Receivable

329 k193 k250 k


893 k1.6 m1.4 m

Current Assets

76.2 m107 m69.9 m


1.8 m3.1 m3.3 m

Total Assets

78.2 m110.3 m74.9 m

Accounts Payable

1.3 m2 m2.1 m

Current Liabilities

5.9 m5.4 m8.3 m

Total Liabilities

22.9 m

Additional Paid-in Capital

148.1 m218.8 m225.9 m

Retained Earnings

(89.4 m)(129.2 m)(173.9 m)

Total Equity

58.7 m89.6 m52 m

Financial Leverage

1.3 x1.2 x1.4 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(28.6 m)(39.7 m)(44.7 m)

Depreciation and Amortization

547 k754 k881 k

Accounts Receivable

(79 k)136 k(57 k)


(36 k)(53 k)924 k

Accounts Payable

507 k348 k(159 k)

Cash From Operating Activities

(20.5 m)(33.7 m)(34 m)

Purchases of PP&E

(1.3 m)(1.8 m)(1.9 m)

Cash From Investing Activities

(38.6 m)(38.6 m)35.6 m

Cash From Financing Activities

79 m65.7 m585 k

Interest Paid

844 k1.3 m1.3 m
Y, 2016

Financial Leverage

1.4 x

Ocular Therapeutix Market Value History

Ocular Therapeutix Company Life and Culture

You may also be interested in